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ABSTRACT We carried out multilocus sequence typing (MLST) on 148 pneumococcal carriage isolates collected from children
<24 months old in the Upper River Division, the Gambia. MLST revealed a diverse population. Seventy-six different sequence
types (STs) were found, the most common of which were 802 and 919, associated with 23F and 6A serotypes, respectively. Com-
parison with theMLST database showed that only 11 of the STs found in the present sample had been reported outside Africa.
Six STs showed evidence of capsular switching (172, 802, 847, 1730, 1736, and 1737). Serotype switches were confirmed bymi-
croarrays that detected capsule genes. Of isolates analyzed by using microarrays, 40/69 (58%) harbored the tetM resistance deter-
minant. A statistical genetic analysis to detect recombination found that 49/144 (34%) isolates showed significant (P< 0.05) evi-
dence of admixture, which is greater than that observed in similar samples from the United Kingdom (5%) and Finland (2%).
We hypothesize that large amounts of admixture could reflect the high prevalence of multiple carriage in this region, leading to
more opportunities for homologous recombination between strains. This could have consequences for the population response
to conjugate vaccination.
IMPORTANCE The population structure of the pneumococcus in sub-Saharan Africa has barely been studied despite the high lev-
els of morbidity andmortality due to pneumococcal disease in this region.We report the largest sample to date from carriage in
sub-Saharan Africa to be typed by sequencing (multilocus sequence typing [MLST]) andmicroarray analysis. The results clearly
show that the population is highly distinct and divergent from others studied in the United States and Europe. Moreover, in con-
trast with samples from developed countries, the population contains a high proportion of isolates showing a history of homolo-
gous recombination, which shuffles genetic information into new combinations and can generate drug-resistant and vaccine
escape strains. This is likely to have important consequences for the evolutionary response of the pneumococcal population to
conjugate vaccination targeting a subset of pneumococcal serotypes, which is under way in the Gambia and other countries.
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The pneumococcus (Streptococcus pneumoniae) is a major pe-diatric pathogen, estimated to be responsible for mortality in
excess of 800,000 per annum in children under 5 years and a par-
ticular threat in sub-Saharan Africa, where the burden of disease is
concentrated (1). Despite this sobering toll, the vast majority of
the pneumococcal population is found in asymptomatic nasopha-
ryngeal carriage, which is responsible for almost all transmission
and is a prerequisite for the development of invasive disease (2). It
is known that pneumococcal serotypes vary in their propensity to
cause invasive disease, with some (notably serotypes 1 and 5) be-
ing associated with a considerably higher invasive potential (3–7).
Samples collected from invasive disease are therefore not repre-
sentative of the carried population. Moreover, the pneumococcal
population is diverse, and serotypes are frequently composed of
multiple distinct lineages (8, 9).
To date, few data exist on the carriage population of pneumo-
cocci in sub-Saharan Africa, despite the great mortality in this
region due to this pathogen. It is known that some serotypes that
are comparatively rare in European or North American settings
cause a greater proportion of disease in Africa (10), and the sero-
types found in carriage are expected to differ accordingly. How-
ever, it is possible that the lineages making up those serotypes also
found commonly in Europe and North America could be similar
to those found in those settings or quite distinct. For example, it
has been shown that serotype 1 is divided into two well-supported
relatively distantly related clades, one of which is associated with
North America and the United Kingdom and the other of which is
associated with Africa and Europe (11). Similarly, sequence type
(ST) 458 has been shown to be responsible for a high proportion
of serotype 3 cases of invasive pneumococcal disease (IPD) in
South Africa (12), whereas in other settings the distantly related
ST 180 is by far the most common clone in this serotype.
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Another feature of pneumococcal carriage in sub-Saharan Af-
rica is the comparatively high rate of colonization with multiple
serotypes or strains (13, 14). In combination with the very high
carriage rate, it is expected that this could offer more opportuni-
ties for homologous recombination between pneumococcal
strains. The pneumococcus is naturally competent, and recombi-
nation is known to be an important factor in its population genet-
ics (9). Recombination can have major clinical consequences by
spreading antibiotic resistance (15) and enabling serotype switch-
ing, in which the capsular biosynthetic locus is replaced with the
corresponding locus from another serotype (16). Serotype switch-
ing has been reported to allow vaccine escape by some important
resistant strains (17–19). Though it has been proposed that some
pneumococcal strains are more likely than others to be involved in
recombination (20), whether there is geographical variation in the
genotypes showing a history of recombination is largely un-
known. The degree to which recombination can contribute to the
diversification of pneumococcal clones has recently been illumi-
nated by the publication of 240 whole genomes of a single lineage,
ST 81 (21). Within a global sample, 74% of the genome had been
involved in recombination in at least one lineage. At present, it is
not clear whether this is true for all pnemococcal lineages or in-
deed whether certain settings might lead to yet more recombina-
tion. However, it illustrates well the contribution made by homol-
ogous recombination to pneumococcal diversification.
Conjugate vaccines against a subset of pneumococcal serotypes
are becoming available to some of those countries with high car-
riage rates that have borne the brunt of pneumococcal morbidity
and mortality, among them the Gambia (where a seven-valent
vaccine was introduced in August 2009). The population structure
of pneumococci in high-carriage environments such as the Gam-
bia has not been extensively studied to date. High rates of multiple
carriage may feasibly have consequences for the extent of homol-
ogous recombination, of relevance to the spread of antibiotic re-
sistance and vaccine escape, as described above. We present a
study of carried pneumococci in children from the Gambia. To
characterize this sample, to compare it with the carriage popula-
tions in other countries, and to detect recombination, we have
applied multilocus sequence typing (MLST).
RESULTS
Serotypes. One hundred forty-eight pneumococcal isolates were
collected from nasopharyngeal carriage in children under 2 years
of age in the Upper River Division, the Gambia. The results of
MLST and serotyping are shown in Table 1, together with the
results of subsequent microarray analysis. The most common se-
rotype was 6A (50/148). Microarray analysis was used to confirm
the serotype of 69 isolates for which independent evidence of the
observed ST/serotype combination was not available. In cases
where multiple serotypes were detected by microarray analysis,
the ST was assigned a serotype as described in Materials and Meth-
ods. It was not possible to determine the serotypes for three iso-
lates (PNC 179, PNC 31, and PNC 203). It is possible that some of
those isolates originally classified as 6A were the recently described
serotype 6C. Microarray analysis of DNA from 17 of these isolates
(representing 14 different STs) confirmed them all as consistent
with 6A (Table 1). No instances of 6C were found. After 6A, the
next most common serotypes were 19F (18/148), 19A (14/148),
23F (11/148), and 14 (8/148), which pooled together make up
68% of the data set. Notably, these are all relatively common se-
rotypes in samples from unvaccinated subjects in the United
States and Europe (for examples, see references 22 to 24).
MLST. The STs for all samples are presented along with the
serotype data in Table 1. A total of 76 different STs were found, the
most common of which were 802 and 919, which were associated
mainly with 23F and 6A serotypes, respectively. Only 11 STs in the
sample were present in the MLST database from non-African
sources at the time of writing. Six STs (172, 802, 847, 1730, 1736,
and 1737) were found expressing more than one serotype, indi-
cating a history of serotype switching. STs 802 and 847 expressed
both 19A and 23F, STs 1730 and ST 1736 expressed both 6A and
6B, ST 172 expressed 23F and 19F, and ST 1737 expressed 6A and
24A capsules.
Multiple carriage. Of the 69 samples selected for microarray
analysis, 13 (19%) were found to contain evidence for coloniza-
tion by more than one serotype, reflecting the high rate of multiple
carriage in this setting. This was despite selection of a single colony
for serotyping and DNA extraction. The observed ST was in al-
most all cases concordant with the majority serotype according to
microarray analysis (Table 1). In cases where it was not, the sam-
ple was not included in further analyses.
eBURST analysis. STs were grouped into clonal complexes
(CCs) of closely related strains in a “population snapshot” of the
entire sample (Fig. 1) using eBURST. The largest clonal complex
found in the data contained ST 912. Table 1 shows that almost half
the 6A isolates in the sample are in the clonal complex descending
from ST 912 (24/50, 48%). Most STs in the sample are singletons,
or STs with no close relatives in the sample. This reflects a highly
diverse population and contrasts with carriage samples from set-
tings in the United States and Europe.
As noted above, the specific STs present are also different and
divergent from those collected in other settings. Even among se-
rotypes such as 19F, 23F, 19A, and 6A, which are common in both
this sample and samples from the United States and Europe, the
vast majority of STs shown in Table 1 have not been found in the
United States or Europe despite intensive sampling in these re-
gions. The divergence is shown in Fig. 2, in which the sample is
compared with the contents of the entire MLST database (as of
14 April 2010). The STs found in the samples described here are
shown surrounded by a pink identifier. The majority are not as-
sociated with the major clonal complexes, which are easily identi-
fied. The 6A clonal complex found in this work descending from
ST 912 (visible on the edge of the diagram at one o’clock) is not
found to be associated with any larger clonal complex or group of
STs. ST 63 is found in association with a serotype 14 capsule,
which is consistent with other studies of the carried pneumococcal
population in the Gambia (8). However, ST 63, in samples from
the United Kingdom and Europe, is typically associated with a 15A
capsule (for example, see reference 25).
Antibiotic resistance. The microarray that was used to ascer-
tain serotypes is also able to detect the genes associated with some
antibiotic resistance determinants. The presence or absence of the
aphA3, cat, ermB, ermC, mefA, sat4, tetK, tetL, tetM, and tetO loci
is shown in Table 1. Of the 69 isolates that were selected for further
testing to confirm serotype, 41 (59%) were found to harbor one of
the above loci. The most common determinant was tetM, which
was found in all but one of these, in five cases along with cat and in
one with tetL. A single example of an isolate carrying cat and no
other resistance loci was detected.
Donkor et al.
2 ® mbio.asm.org May/June 2011 Volume 2 Issue 3 e00040-11
TABLE 1 MLST serotype, microarray, and admixture results
Strain name ST aroE gdh gki recP spi xpt ddl Serotypea Commentb Resistance locus or locic Significantly admixedd
PNC 64 458 2 32 9 47 6 21 17 3 ND No
PNC 14 923 13 5 1 1 15 1 18 13 Serotype verified by microarray  No
PNC 54 2180 50 9 123 10 15 167 74 13 Serotype verified by microarray tetM No
PNC 74 63 2 5 36 12 17 21 14 14 ND No
PNC 23 63 2 5 36 12 17 21 14 14 ND No
PNC 92 63 2 5 36 12 17 21 14 14 Serotype verified by microarray tetM No
PNC 31 908 2 5 36 12 2 21 123 14 Serotype verified by microarray tetM No
PNC 285 915 6 60 4 5 27 123 6 14 Serotype verified by microarray  No
PNC 311 915 6 60 4 5 27 123 6 14 ND No
PNC 327 915 6 60 4 5 27 123 6 14 ND No
PNC 347 915 6 60 4 5 27 123 6 14 ND No
PNC 55 2169 7 5 4 1 1 20 11 21 Serotype verified by microarray  No
PNC 332 1746 10 13 4 16 15 1 6 21 ND No
PNC 294 1745 8 9 52 5 10 122 11 28 ND Yes
PNC 283 1778 2 5 54 38 27 88 6 34 Serotype verified by microarray  
PNC 9 1788 5 5 4 50 6 1 18 34 ND 
PNC 66 2159 5 15 4 16 6 1 6 38 Serotype verified by microarray tetM No
PNC 69 2159 5 15 4 16 6 1 6 38 Serotype verified by microarray tetM No
PNC 189 2159 5 15 4 16 6 1 6 38 Serotype verified by microarray tetM No
PNC 89 393 10 43 41 18 13 49 6 38 Serotype verified by microarray  No
PNC 237 909 2 42 2 1 6 19 20 10F Serotype verified by microarray  No
PNC 236 909 2 42 2 1 6 19 20 10F ND No
PNC 287 989 12 5 89 8 6 112 14 12F ND Yes
PNC 338 989 12 5 89 8 6 112 14 12F ND Yes
PNC 73 989 12 5 89 8 6 112 14 12Fe 12F (88%) 15C (12%) cat tetM Yes
PNC 81 916 7 5 4 4 15 20 14 15A ND No
PNC 96 917 7 5 4 4 15 20 5 15A ND No
PNC 204 1738 7 5 1 4 15 20 5 15A ND No
PNC 38 1727 60 82 4 4 6 1 18 15B Serotype verified by microarray cat tetM No
PNC 208 1748 12 111 9 84 6 83 74 16F Serotype verified by microarray  Yes
PNC 244 927 23 12 4 1 43 12 74 16F Serotype verified by microarray  Yes
PNC 250 924 13 8 69 1 6 1 6 17F Serotype verified by microarray  No
PNC 18 924 13 8 69 1 6 1 6 17F ND No
PNC 19 1233 10 11 34 16 15 1 145 18C Serotype verified by microarray tetM No
PNC 30 1233 10 11 34 16 15 1 145 18C Serotype verified by microarray tetM No
PNC 325 2167 7 5 1 2 6 112 6 19A Serotype verified by microarray  No
PNC 345 2168 7 5 4 1 6 112 14 19A ND No
PNC 336 847 7 11 4 1 6 112 14 19A Serotype verified by microarray  No
PNC 339 847 7 11 4 1 6 112 14 19A ND No
PNC 1 847 7 11 4 1 6 112 14 19A ND No
PNC 29 847 7 11 4 1 6 112 14 19A ND No
PNC 39 847 7 11 4 1 6 112 14 19A ND No
PNC 211 847 7 11 4 1 6 112 14 19A ND No
PNC 320 847 7 11 4 1 6 112 14 19A ND No
PNC 292 921 7 78 4 1 6 112 14 19A Serotype verified by microarray  No
PNC 302 921 7 78 4 1 6 112 14 19A Serotype verified by microarray  No
PNC 329 1787 8 13 7 16 36 173 6 19A Serotype verified by microarray  
PNC 111 802 10 13 53 1 72 38 31 19A ND Yes
PNC 45 802 10 13 53 1 72 38 31 19A ND Yes
PNC 301 1786 2 5 4 10 17 1 198 19F Serotype verified by microarray tetM No
PNC 227 2170 7 5 4 4 6 20 14 19F Serotype verified by microarray  No
PNC 112 172 7 13 8 6 25 6 8 19F Serotype verified by microarray tetM Yes
PNC 219 925 15 16 19 15 6 20 19 19F ND No
PNC 42 925 15 16 19 15 6 20 19 19F ND No
PNC 61 925 15 16 19 15 6 20 19 19F ND No
PNC 34 925 15 16 19 15 6 20 19 19F Serotype verified by microarray tetM No
PNC 334 926 15 16 19 15 6 20 14 19F ND No
PNC 221 926 15 16 19 15 6 20 14 19F ND No
PNC 272 928 53 76 8 15 6 20 19 19F Serotype verified by microarray tetM No
PNC 276 928 53 76 8 15 6 20 19 19F Serotype verified by microarray tetM No
PNC 331 929 53 76 19 15 6 20 19 19F ND No
PNC 41 929 53 76 19 15 6 20 19 19F ND No
PNC 303 929 53 76 19 15 6 20 19 19F ND No
PNC 333 929 53 76 19 15 6 20 19 19F ND No
PNC 21 929 53 76 19 15 6 20 19 19F Serotype verified by microarray tetM No
Continued on following page
Recombination in Gambian Pneumococci
May/June 2011 Volume 2 Issue 3 e00040-11 ® mbio.asm.org 3
TABLE 1—Continued
Strain name ST aroE gdh gki recP spi xpt ddl Serotypea Commentb Resistance locus or locic Significantly admixedd
PNC 35 929 53 76 19 15 6 20 19 19F Serotype verified by microarray tetM No
PNC 5 929 53 76 19 15 6 20 19 19F Serotype verified by microarray tetM No
PNC 228 1777 5 5 8 88 9 1 31 20e 20 (94%) 19F (5%) 9L (1%) tetM (19F) 
PNC 32 1746 10 13 4 16 15 1 6 21e 21 (93%) 19A (7%) tetL tetM No
PNC 53 910 5 5 6 5 9 17 19 22A Serotype verified by microarray  Yes
PNC 312 802 10 13 53 1 72 38 31 23A ND Yes
PNC 214 2160 6 5 5 5 27 3 5 23F ND No
PNC 258 2160 6 5 5 5 27 3 5 23F ND No
PNC 179 847 7 11 4 1 6 112 14 23F ND No
PNC 107 172 7 13 8 6 25 6 8 23F ND Yes
PNC 234 2174 7 16 8 8 6 142 14 23F ND No
PNC 233 802 10 13 53 1 72 38 31 23F ND Yes
PNC 243 802 10 13 53 1 72 38 31 23F ND Yes
PNC 255 802 10 13 53 1 72 38 31 23F ND Yes
PNC 44 802 10 13 53 1 72 38 31 23F Serotype verified by microarray tetM Yes
PNC 47 802 10 13 53 1 72 38 31 23F Serotype verified by microarray tetM Yes
PNC 65 802 10 13 53 1 72 38 31 23Fe 23F (74%) 38 (26%) tetM Yes
PNC 46 1737 6 57 34 28 6 1 9 24A Serotype verified by microarray tetM Yes
PNC 75 1747 10 16 54 10 7 1 31 35A Serotype verified by microarray  Yes
PNC 254 1740 7 13 4 5 6 122 18 35B ND No
PNC 43 2157 1 8 36 5 9 60 14 6A Serotype verified by microarray tetM No
PNC 217 1730 2 5 4 10 17 1 8 6A ND No
PNC 307 1730 2 5 4 10 17 1 8 6A ND No
PNC 289 2161 6 15 34 28 6 1 9 6A ND No
PNC 71 911 6 57 34 58 6 1 9 6A ND Yes
PNC 80 912 6 57 34 28 7 1 9 6A ND Yes
PNC 82 912 6 57 34 28 7 1 9 6A ND Yes
PNC 94 912 6 57 34 28 7 1 9 6A ND Yes
PNC 212 912 6 57 34 28 7 1 9 6A ND Yes
PNC 215 912 6 57 34 28 7 1 9 6A ND Yes
PNC 220 912 6 57 34 28 7 1 9 6A Serotype verified by microarray tetM Yes
PNC 253 913 6 57 83 28 7 19 9 6A ND Yes
PNC 256 914 6 57 83 28 7 1 9 6A ND No
PNC 279 914 6 57 83 28 7 1 9 6A Serotype verified by microarray tetM No
PNC 11 1736 6 57 34 1 7 1 74 6A ND Yes
PNC 218 1736 6 57 34 1 7 1 74 6A ND Yes
PNC 242 1736 6 57 34 1 7 1 74 6A ND Yes
PNC 180 1736 6 57 34 1 7 1 74 6A ND Yes
PNC 223 1737 6 57 34 28 6 1 9 6A Serotype verified by microarray cat tetM Yes
PNC 6 1737 6 57 34 28 6 1 9 6A ND Yes
PNC 37 1737 6 57 34 28 6 1 9 6A ND Yes
PNC 67 1737 6 57 34 28 6 1 9 6A ND Yes
PNC 298 2162 6 57 34 1 7 1 8 6A ND Yes
PNC 308 2163 6 57 34 28 6 1 19 6A ND Yes
PNC 309 2164 6 57 34 28 7 1 18 6A Serotype verified by microarray cat tetM Yes
PNC 310 2165 6 57 34 28 7 1 8 6A ND Yes
PNC 323 2166 6 57 34 28 7 1 14 6A ND Yes
PNC 2 2171 7 8 1 2 15 60 14 6A Serotype verified by microarray tetM No
PNC 10 2173 7 13 1 5 42 60 31 6A ND No
PNC 12 2173 7 13 1 5 42 60 31 6A ND No
PNC 206 2173 7 13 1 5 42 60 31 6A ND No
PNC 28 919 7 25 29 2 27 122 122 6A Serotype verified by microarray  No
PNC 27 919 7 25 29 2 27 122 122 6A Serotype verified by microarray  No
PNC 24 919 7 25 29 2 27 122 122 6A Serotype verified by microarray  No
PNC 239 919 7 25 29 2 27 122 122 6A ND No
PNC 240 919 7 25 29 2 27 122 122 6A ND No
PNC 319 919 7 25 29 2 27 122 122 6A ND No
PNC 328 919 7 25 29 2 27 122 122 6A ND No
PNC 4 919 7 25 29 2 27 122 122 6A ND No
PNC 321 919 7 25 29 2 27 122 122 6A ND No
PNC 198 920 7 25 29 2 27 112 122 6A ND No
PNC 281 1741 7 25 29 2 112 172 122 6A Serotype verified by microarray  Yes
PNC 286 1785 7 25 29 1 36 122 197 6A Serotype verified by microarray  No
PNC 306 2175 7 25 29 1 36 122 18 6A Serotype verified by microarray  No
Continued on following page
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Recombination. To quantify the contribution made by ho-
mologous recombination to the carried population in the Gam-
bia, the STs were compared with the previously published results
of an analysis of the whole pneumococcal MLST database using
the BAPS package (20). This analysis identifies STs with evidence
of admixture—meaning in this case recombination. The results
are shown in Table 1. Four STs (1777, 1778, 1787, and 1788) were
not present in the MLST database at the time of the original BAPS
analysis and have been excluded. Forty-nine of 144 (34%) isolates
in the Gambian sample showed significant (P 0.05) evidence of
admixture.
DISCUSSION
Despite several recent publications studying the pneumococcal
population in sub-Saharan Africa (8, 13, 14, 26, 27), this region
remains undersampled in general in relation to the amounts of
invasive disease that occur there (1). In this paper, we present a
sample from children under 2 years of age from the Gambia. All
isolates have been characterized using MLST, which allows us to
examine relationships between strains in the data set and also
relationships with the MLST database, which contains isolates
from many other countries. This is to date the largest carriage
sample from sub-Saharan Africa to have been typed by MLST and
hence reflects one of the best insights into the population structure
of this important pathogen in the region where it exacts its greatest
toll.
One of the most striking findings of this work is the difference
between the STs found in the samples here and the more inten-
sively sampled locations in the United States and Europe. This can
be illustrated by comparison with the MLST database, which re-
cords MLST and epidemiological data from researchers in multi-
ple labs and continents (http://spneumoniae.mlst.net/). Because
submission of MLST data is voluntary, the database is far from an
ideal sample of pneumococcal global diversity, but it nevertheless
allows us to ask whether an ST or lineage is sufficiently common to
have been sampled. The vast majority of records reflect the major-
ity of pneumococcal research from developed countries, with
5,102 of 7,278 records for which location data are available at the
time of writing being from Europe or North America. The diverse
nature of the sample set that we describe here, in contrast with the
large clonal complexes that make up the majority of the MLST
database, is evident in Fig. 2. Also evident is the high frequency of
6A in this sample, in the largest clonal complex and several unre-
TABLE 1—Continued
Strain name ST aroE gdh gki recP spi xpt ddl Serotypea Commentb Resistance locus or locic Significantly admixedd
PNC 282 1742 7 57 83 28 7 1 8 6A Serotype verified by microarray cat tetM Yes
PNC 225 1750 75 6 1 2 6 1 14 6A ND No
PNC 245 912 6 57 34 28 7 1 9 6Ae 6A (87%) 19F (13%) tetM (6A) Yes
PNC 249 912 6 57 34 28 7 1 9 6Ae 6A (84%) 19F (16%) tetM (6A) cat (19F) Yes
PNC 7 2172 7 8 54 6 15 60 18 6Ae 6A (79%) 19F (21%) tetM Yes
PNC 291 920 7 25 29 2 27 112 122 6Ae 6A (93%) NT3b (7%) cat (NT3b) No
PNC 203 1730 2 5 4 10 17 1 8 6B Serotype verified by microarray tetM No
PNC 25 273 5 6 1 2 6 1 14 6B ND No
PNC 251 1736 6 57 34 1 7 1 74 6B ND Yes
PNC 190 2178 10 20 14 1 6 20 29 7F Serotype verified by microarray tetM Yes
PNC 36 1735 6 5 2 5 36 1 5 9Le 9L (95%) 6A (5%) tetM (6A) No
PNC 324 1871 1 16 4 10 7 1 31 9V Serotype verified by microarray tetM No
PNC 50 1871 1 16 4 10 7 1 31 9V Serotype verified by microarray tetM No
PNC 230 2179 15 17 4 4 6 1 17 9Ve 9V (86%) 6A (14%)  No
PNC 57 1728 8 77 84 1 10 171 72 NT3a Serotype verified by microarray  Yes
PNC 40 922 8 5 15 10 2 1 59 NT3b Serotype verified by microarray  No
PNC 13 918 7 13 8 6 9 6 14 U 46 (66%) 21 (34%)  Yes
PNC 290 2176 8 5 2 16 1 26 1 U 46 (59%) 21 (41%)  No
PNC 60 2177 8 5 54 10 7 1 168 U 22A (56%) 11D (44%) tetM Yes
a Serotype was determined as described in Materials and Methods.
b Indicates whether microarray was used to confirm serotype. Where signal from more than one capsule was found, the proportions are identified.
c The presence of resistance loci and (if relevant) which serotype they were associated with., no resistance loci were identified. ND, not done.
d Whether the ST was previously identified (20) as showing significant admixture., data not available.
e Isolates which were found to be mixed as described in Comment column. U, serotype was unclassifiable.
FIG 1 Population snapshot of the Gambian carriage sample. Each ST is
represented by a point, the size of which is determined by the number of
isolates with that ST in the combined data set. STs differing at a single genetic
locus are linked by a straight line. A clonal complex (CC) is a group of STs
sharing 6 of 7 alleles with at least one other member of the group. The putative
ancestral ST of each CC is shown in blue, with subgroup ancestors shown in
yellow. Those STs that cannot be linked to any other in the sample are termed
singletons and appear as unlinked points. For more information see http:
//spneumoniae.mlst.net/eburst/.
Recombination in Gambian Pneumococci
May/June 2011 Volume 2 Issue 3 e00040-11 ® mbio.asm.org 5
lated (singleton) lineages (Fig. 1). This observation suggests that
6A may have been common for some time, in order to have gen-
erated such diversity.
We have also found evidence of a high prevalence of resistance
to at least some antibiotics. It is not possible to determine the
precise prevalence of the resistance determinants detected by the
microarray, because the isolates tested were chosen not for this
purpose but in order to verify their serotype and as a result are a
biased sample of the carriage population. However, it is reason-
able to conclude that tetM prevalence is very high. If we assume
that resistance is predominantly a clonal property, and that all
isolates with STs which were found to be tetM also contained this
locus, then we can estimate that at least 68/148 of the Gambian
carriage samples were resistant to tetracycline. This takes no ac-
count of other resistance determinants, nor of the possibility that
other STs, closely related to those found with the tetM locus, are
also resistant. With this in mind, it should be noted that ST 912,
the most common ST in the data set and the inferred ancestor of
the only clonal complex within it (Fig. 1), was found to carry tetM.
It may be counted as surprising that the combination of ermBwith
tetM, frequent in other samples, was not noted here. At present,
we cannot be sure whether this was due to the absence of the ermB
resistance locus or the presence of a highly divergent ermB locus
that could not be detected by our methods. The nature of the
region harboring tetM resistance in these strains is currently being
investigated.
From the data presented here, we cannot conclude whether the
prevalence and wide phylogenetic distribution of these resistance
determinants are associated with recombination, but we have
good evidence that recombination has made a considerable con-
tribution to the Gambian pneumococcal population. This is par-
ticularly evident if we compare previously published carriage data
sets from Finland (6) and Oxford, United Kingdom (23). In the
Oxford data set, 14/264 (5%) isolates were associated with an in-
ferred history of admixture, while this was true for just 4/217 (2%)
isolates in the Finnish sample. This should be compared with 49/
144 (34%) isolates in this sample. That recombination in sub-
Saharan Africa might be more common than elsewhere is perhaps
not surprising given the high rates of carriage and the relatively
high frequency with which multiple serotypes are carried in this
setting, as directly if inadvertently detected in 13 of 69 (19%)
samples subjected to microarray analysis. In contrast, in a recent
study using the microarray in combination with other methods to
examine multiple carriage among Swiss outpatients, only 7.9% of
those carrying pneumococci showed evidence of more than one
serotype being present (28). However, we emphasize that the sam-
ples and methods used in that study were not identical to those
that we employed. In those cases of multiple carriage detected in
our data set, a clear MLST profile was determined despite the clear
presence of DNA from more than one serotype. While it might be
expected that sequencing would detect mixed cultures as generat-
ing mixed sequence, the ability of sequencing to detect the pres-
ence of minority DNA has not been systematically studied, and
this may suggest that mixed DNA samples in other data sets are
more common than is immediately apparent from MLST analysis.
In order for strains to undergo recombination, they must co-
colonize the same host, and the high rate of multiple carriage is
expected to provide more opportunities for this to occur. As noted
below, the STs found in this paper (and others) are divergent from
those that have been recorded to date. This may be partially a
consequence of the high rate of recombination, which will gener-
ate novel combinations of the alleles at the MLST loci. As noted by
Croucher et al. (21), recombination in the pneumococcus is capa-
ble of generating considerable adaptation over a time scale of a few
decades, and within high-carriage settings, this could be enhanced
by more opportunities for homologous recombination.
Examining the MLST database, we note that the most common
ST in this sample (ST 919) has been recorded only in the Gambia,
as is also the case for ST 912 (the predicted ancestor of the largest
clonal complex shown in Fig. 1 and divergent from STs in the
FIG 2 Comparison of the STs shown in Figure 1 with the whole MLST data set (as of 20 April 2010). Clonal complexes are defined as described above. STs found
in this work are shown surrounded by pink.
Donkor et al.
6 ® mbio.asm.org May/June 2011 Volume 2 Issue 3 e00040-11
MLST database as shown in Fig. 2). Similarly striking is the obser-
vation that the common 23F clone ST 802 has been recorded only
once in the United States or Europe. At the time of writing, 26
isolates of ST 802 are present in the MLST database. Of these, 13
are African in origin, being from other studies in the Gambia or
Niger (http://spneumoniae.mlst.net). However, it is particularly
striking that 10 additional records (at the time of writing) of ST
802 in carriage come from studies in the Mae La refugee camp in
Thailand (http://spneumoniae.mlst.net). A direct epidemiologi-
cal link between these settings is hard to envisage. That a clone
should be common in such distant locations suggests the intrigu-
ing possibility that some pneumococcal lineages are adapted to
settings other than those that have been extensively studied to
date. Certain host genotypes predispose to invasive pneumococcal
disease (29), but no association is known between host genotype
and carriage. Figure 2 shows that the STs found in this work are
comparatively divergent from the rest of the MLST database, and
other MLST studies on strains from the Gambia have also found a
large proportion of STs that had not previously been recorded (8);
the vast majority of pneumococcal morbidity and mortality falls
in locations such as sub-Saharan Africa. If the pneumococcal pop-
ulation found in these regions is distinct, it is possible that it might
also differ in terms of invasiveness. Whether or not this is the case
can only be resolved by improved sampling of carriage and disease
from those locations where most pneumococcal disease occurs.
MATERIALS AND METHODS
Strains. Nasopharyngeal swab samples were collected from children un-
der 2 years of age in the Upper River Division, the Gambia. While the
children themselves were unimmunized, prior to delivery their mothers
had received a 9-valent pneumococcal conjugate vaccine (30). Pneumo-
cocci were identified on gentamicin (5 mg/ml) sheep blood agar by their
morphological characteristics and optochin sensitivity. Serotyping was
performed on site, with capsular and factor typing sera (Statens Serum
Institut) using the latex agglutination technique (26). Isolates with equiv-
ocal serotyping results were rechecked by Quellung reaction. A single
colony was picked, and DNA was extracted for MLST as previously de-
scribed (31). The Medical Research Council (MRC) microbiology labo-
ratory is enrolled in the external quality assurance program of the United
Kingdom National External Quality Assessment Scheme (http://www
.ukneqas.org/uk). The study was approved by the Joint Gambian Govern-
ment and MRC Ethics Committee and the Ethics Committees of the Lon-
don School of Hygiene and Tropical Medicine.
MLST. Sequence types (STs) of isolates were determined by MLST as
previously described (31). Sequences of each of the seven gene fragments
used in the pneumococcal MLST scheme were obtained on both DNA
strands with an ABI 3700 DNA analyzer. The sequences were aligned and
trimmed to defined start and end positions using MEGA version 4 (32).
Allele and ST assignments were made using the MLST website (http:
//spneumoniae.mlst.net). All alleles not already present in the pneumo-
coccal MLST database were verified by resequencing the gene fragment on
both strands.
Microarray analysis to confirm serotype. In all cases where the re-
ported serotype was discordant with that expected either from identical or
closely related STs in the sample or the MLST database, the isolate was
reserotyped. In 20 cases this was not possible because of loss of the original
culture. In these cases, the DNA used for MLST was applied to a microar-
ray designed to allow the unique combinations of genes determining cap-
sular type to be identified (28, 33). This revealed a high rate of error in the
original serotyping results, and as a result, microarray analysis was used to
confirm the serotype of all MLST types for which there was no indepen-
dent evidence for that serotype/ST combination (i.e., STs found only
once, and with no close relatives either in the data set here or in the
database). Where the microarray identified DNA from more than one
capsular type (the result of a mixed culture), the isolate was recorded as
the majority serotype if it was responsible for 70% of the signal. In all
cases where the majority serotype was responsible for70% of the signal,
the isolate was recorded as unclassified. In addition to loci for serotype
assignment, the microarray also contained the aphA3, cat, ermB, ermC,
mefA, sat4, tetK, tetL, tetM, and tetO genes, allowing the presence and
transfer of these antibiotic resistance genes to be assessed.
eBURST and detection of recombination. The population structure
of the samples was analyzed using eBURST (34). This program groups
related STs into clonal complexes (CCs), identifies the probable ancestor
of each CC as the ST with the largest number of minor differences, and
outputs a graphical representation of these relationships.
To assess the impact of recombination on the population, the STs
found in this work were compared with the results of a previously pub-
lished analysis of the entire MLST database using the program Bayesian
Analysis of Population Structure (BAPS) (35–37). This program divides a
data set into populations on the basis of allele frequencies and identifies
significantly (P  0.05) admixed genotypes that contain sequence char-
acteristic of more than one population.
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